Aims To examine the relationship between proguanil metabolism and the number of mutations in CYP2C19 by comparing the CYP2C19 genotype and proguanil phenotype of 10 subjects. Methods Partial clearance and urinary metabolic ratio data were obtained from a previous study of 10 subjects [5]. Analysis of CYP2C19 genotypes was performed using PCR amplification followed by restriction endonuclease digestion of genomic DNA from a blood sample. Results The intrinsic partial clearance of PG to CG ranged from 0.41-10.1l h −1 , and was related to the number of functional CYP2C19 alleles present. Genotypic PMs had metabolic ratios >13, while genotypic heterozygote EMs had metabolic ratios <9.
Introduction tion (PCR) amplification of 100ng genomic DNA in 1× Taq reaction buffer (67 mm pH 8.8, 16 .6 mm The S-mephenytoin hydroxylation genetic polymorphism has been reported to be due to two mutations of the (NH 4 ) 2 SO 4 , 0.2 mg ml −1 gelatin, 0.45% Trixon X-100) (Bresatec, Adelaide, Australia), 50 mm of dATP, dCTP, CYP2C19 gene, notably CYP2C19*2 (m1) located in exon 5, and CYP2C19*3 (m2) located in exon 4 [1] . dGTP, and dTTP (Pharmacia Biotech, North Ryde, Australia), 2 mm MgCl 2 , 0.25 mm PCR primers, identical to Together these mutations account for 100% of mutant alleles in Japanese subjects. In Caucasian subjects m2 is absent and those used by de Morais and colleagues [6] , and 2.5 units of Taq DNA Polymerase (Bresatec, Adelaide, Australia). m1 accounts for only 75-80% of mutant alleles implying the presence of unidentified mutations [1] . Various studies Amplification was performed with a Perkin Elmer DNA thermal cycler under conditions used by de Morais and have indicated that proguanil (PG) metabolism to cycloguanil (CG) is at least in part mediated by CYP2C19 [2, 3, 4] . A colleagues [6] . PCR CYP2C19*2 and CYP2C19*3 products were previous study in this laboratory [5] showed a >10-fold variation in PG and CG disposition in 10 healthy subjects, digested by Sma I and Bam HI restriction endonucleases (Bresatec, Adelaide, Australia), respectively, and products with a strong relationship between the urinary metabolic ratio (PG/CG) and intrinsic clearance (CL int ) for PG were analysed by gel electrophoresis using a 4% NuSieveA 351 Agarose gel (FMC BioProducts, ME, USA). Genotyping formation. However, we were unable to assign phenotype status as the antimode of the metabolic ratio remains unclear.
results were confirmed by automated DNA sequencing analysis following purification with Microcon TM This study reports the comparison of the genotype of CYP2C19 and phenotype in these 10 subjects. Microconcentrators (Amicon, USA), and compared to the published sequences [1, 7] .
Methods
The study was approved by the Royal Adelaide Hospital Results Research Ethics Committee. Partial clearance and metabolic Table 1 shows the proguanil pharmacokinetic data and the ratio data from a previous study in which 10 subjects CYP2C19 genotyping data. Intrinsic partial clearance to CG received a single 100 mg oral dose of proguanil hydrochloride and the metabolic ratio (PG/CG) of the 10 subjects ranged (PaludrineA; ICI Pharmaceuticals) were used [5] . Genomic from 0.41-10.1 l h −1
, and from 18.1-0.93, respectively. DNA was isolated from a blood sample from each subject
The genotyping assay detected the presence of CYP2C19*1 using a QIAampA blood kit (QIAGEN Inc., CA, USA).
(wildtype) and CYP2C19*2 (mutation m1) alleles, but no Genotyping for the two genetic mutations (CYP2C19*2, CYP2C19*3 (mutation m2) alleles were observed in any of the subjects. Comparison between the pharmacokinetic and genotyping data reveals that the number of functional (CYP2C19*1/CYP2C19*1) had the highest clearance and
